In this issue:
Ixekizumab vs guselkumab for moderate-to-severe plaque psoriasis
Cumulative clinical benefits of biologics for psoriasis over 16 weeks
Predictors of hepatitis B and C virus reactivation during biologic therapy
3 years of continuous treatment with guselkumab
Thyroid dysfunction in psoriasis
Association between psoriasis and coeliac disease
Concomitant atopic dermatitis and psoriasis
Ocular findings in patients with psoriasis
Psoriasis and mental health workshop report
Non-alcoholic fatty liver and liver fibrosis in moderate-severe psoriasis
Please login below to download this issue (PDF)